Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01597908




Registration number
NCT01597908
Ethics application status
Date submitted
10/05/2012
Date registered
14/05/2012
Date last updated
24/02/2021

Titles & IDs
Public title
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Scientific title
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Secondary ID [1] 0 0
CDRB436B2302
Secondary ID [2] 0 0
116513
Universal Trial Number (UTN)
Trial acronym
COMBI-v
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dabrafenib
Treatment: Drugs - Vemurafenib
Treatment: Drugs - Trametinib

Experimental: Dabrafenib plus Trametinib - BRAF inhibitor plus MEK inhibitor

Active comparator: Vemurafenib - BRAF inhibitor


Treatment: Drugs: Dabrafenib
Dabrafenib 150 mg twice daily orally

Treatment: Drugs: Vemurafenib
Vemurafenib 960 mg twice daily orally

Treatment: Drugs: Trametinib
Trametinib 2 mg once daily orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From the date of randomization until date of death due to any cause (up to approximately 6 years)
Secondary outcome [1] 0 0
Progression-Free Survival (PFS), as Assessed by the Investigator
Timepoint [1] 0 0
From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Secondary outcome [2] 0 0
Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator
Timepoint [2] 0 0
From randomization until the first documented complete response or partial response (up to approximately 6 years)
Secondary outcome [3] 0 0
Duration of Response (DOR), as Assessed by the Investigator
Timepoint [3] 0 0
From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)

Eligibility
Key inclusion criteria
Key

* >= 18 years of age
* Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
* Measurable disease according to RECIST 1.1
* Women of childbearing potential with negative serum pregnancy test prior to randomisation
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Adequate baseline organ function

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any prior use of a BRAF or MEK inhibitor
* Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed
* History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)
* Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
* Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisation
* History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
* History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/04/2019
Sample size
Target
Accrual to date
Final
704
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - North Sydney
Recruitment hospital [2] 0 0
Novartis Investigative Site - Westmead
Recruitment hospital [3] 0 0
Novartis Investigative Site - Greenslopes
Recruitment hospital [4] 0 0
Novartis Investigative Site - Herston
Recruitment hospital [5] 0 0
Novartis Investigative Site - South Brisbane
Recruitment hospital [6] 0 0
Novartis Investigative Site - Woodville
Recruitment hospital [7] 0 0
Novartis Investigative Site - Box Hill
Recruitment hospital [8] 0 0
Novartis Investigative Site - Melbourne
Recruitment hospital [9] 0 0
Novartis Investigative Site - Nedlands
Recruitment postcode(s) [1] 0 0
2060 - North Sydney
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4120 - Greenslopes
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
5011 - Woodville
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment postcode(s) [9] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
Vermont
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Río Negro
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fe
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma de Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
San Miguel de Tucuman
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Innsbruck
Country [31] 0 0
Austria
State/province [31] 0 0
Salzburg
Country [32] 0 0
Austria
State/province [32] 0 0
Wien
Country [33] 0 0
Belgium
State/province [33] 0 0
Brasschaat
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Brussel
Country [36] 0 0
Belgium
State/province [36] 0 0
Gent
Country [37] 0 0
Belgium
State/province [37] 0 0
Kortrijk
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Namur
Country [40] 0 0
Belgium
State/province [40] 0 0
Wilrijk
Country [41] 0 0
Brazil
State/province [41] 0 0
Rio Grande Do Sul
Country [42] 0 0
Brazil
State/province [42] 0 0
Santa Catarina
Country [43] 0 0
Brazil
State/province [43] 0 0
Sao Paulo - SP
Country [44] 0 0
Canada
State/province [44] 0 0
Alberta
Country [45] 0 0
Canada
State/province [45] 0 0
British Columbia
Country [46] 0 0
Canada
State/province [46] 0 0
Manitoba
Country [47] 0 0
Canada
State/province [47] 0 0
Nova Scotia
Country [48] 0 0
Canada
State/province [48] 0 0
Ontario
Country [49] 0 0
Canada
State/province [49] 0 0
Quebec
Country [50] 0 0
Czechia
State/province [50] 0 0
Olomouc
Country [51] 0 0
Czechia
State/province [51] 0 0
Ostrava
Country [52] 0 0
Czechia
State/province [52] 0 0
Praha 10
Country [53] 0 0
Czechia
State/province [53] 0 0
Praha 2
Country [54] 0 0
Czechia
State/province [54] 0 0
Zlin
Country [55] 0 0
Denmark
State/province [55] 0 0
Arhus C
Country [56] 0 0
Denmark
State/province [56] 0 0
Herlev
Country [57] 0 0
Denmark
State/province [57] 0 0
Odense
Country [58] 0 0
Finland
State/province [58] 0 0
Helsinki
Country [59] 0 0
Finland
State/province [59] 0 0
Jyvaskyla
Country [60] 0 0
Finland
State/province [60] 0 0
Tampere
Country [61] 0 0
Finland
State/province [61] 0 0
Turku
Country [62] 0 0
France
State/province [62] 0 0
Bordeaux
Country [63] 0 0
France
State/province [63] 0 0
Grenoble
Country [64] 0 0
France
State/province [64] 0 0
Lille
Country [65] 0 0
France
State/province [65] 0 0
Marseille cedex 5
Country [66] 0 0
France
State/province [66] 0 0
Montpellier cedex 5
Country [67] 0 0
France
State/province [67] 0 0
Nantes
Country [68] 0 0
France
State/province [68] 0 0
Nice
Country [69] 0 0
France
State/province [69] 0 0
Paris Cedex 10
Country [70] 0 0
France
State/province [70] 0 0
Reims Cedex
Country [71] 0 0
France
State/province [71] 0 0
Rennes Cedex
Country [72] 0 0
France
State/province [72] 0 0
Villejuif cedex
Country [73] 0 0
Germany
State/province [73] 0 0
Baden-Wuerttemberg
Country [74] 0 0
Germany
State/province [74] 0 0
Bayern
Country [75] 0 0
Germany
State/province [75] 0 0
Niedersachsen
Country [76] 0 0
Germany
State/province [76] 0 0
Nordrhein-Westfalen
Country [77] 0 0
Germany
State/province [77] 0 0
Rheinland-Pfalz
Country [78] 0 0
Germany
State/province [78] 0 0
Sachsen-Anhalt
Country [79] 0 0
Germany
State/province [79] 0 0
Sachsen
Country [80] 0 0
Germany
State/province [80] 0 0
Schleswig-Holstein
Country [81] 0 0
Germany
State/province [81] 0 0
Thueringen
Country [82] 0 0
Hungary
State/province [82] 0 0
Budapest
Country [83] 0 0
Hungary
State/province [83] 0 0
Debrecen
Country [84] 0 0
Hungary
State/province [84] 0 0
Gyor
Country [85] 0 0
Hungary
State/province [85] 0 0
Kaposvar
Country [86] 0 0
Hungary
State/province [86] 0 0
Miskolc
Country [87] 0 0
Hungary
State/province [87] 0 0
Szeged
Country [88] 0 0
Ireland
State/province [88] 0 0
Co.Cork
Country [89] 0 0
Ireland
State/province [89] 0 0
Dublin
Country [90] 0 0
Ireland
State/province [90] 0 0
Galway
Country [91] 0 0
Israel
State/province [91] 0 0
Jerusalem
Country [92] 0 0
Israel
State/province [92] 0 0
Ramat Gan
Country [93] 0 0
Italy
State/province [93] 0 0
Campania
Country [94] 0 0
Italy
State/province [94] 0 0
Lazio
Country [95] 0 0
Italy
State/province [95] 0 0
Liguria
Country [96] 0 0
Italy
State/province [96] 0 0
Lombardia
Country [97] 0 0
Italy
State/province [97] 0 0
Toscana
Country [98] 0 0
Italy
State/province [98] 0 0
Veneto
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Goyang-si, Gyeonggi-Do
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Seoul
Country [101] 0 0
Netherlands
State/province [101] 0 0
Amsterdam
Country [102] 0 0
Netherlands
State/province [102] 0 0
Groningen
Country [103] 0 0
Netherlands
State/province [103] 0 0
Leeuwarden
Country [104] 0 0
Netherlands
State/province [104] 0 0
Leiden
Country [105] 0 0
Netherlands
State/province [105] 0 0
Rotterdam
Country [106] 0 0
New Zealand
State/province [106] 0 0
Christchurch
Country [107] 0 0
New Zealand
State/province [107] 0 0
Newtown, Wellington
Country [108] 0 0
Norway
State/province [108] 0 0
Kristiansand
Country [109] 0 0
Norway
State/province [109] 0 0
Lorenskog
Country [110] 0 0
Norway
State/province [110] 0 0
Oslo
Country [111] 0 0
Poland
State/province [111] 0 0
Gdansk
Country [112] 0 0
Poland
State/province [112] 0 0
Konin
Country [113] 0 0
Poland
State/province [113] 0 0
Poznan
Country [114] 0 0
Poland
State/province [114] 0 0
Warszawa
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Chelyabinsk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Magnitogorsk
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Moscow
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Nizhniy Novgorod
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Ryazan
Country [120] 0 0
Russian Federation
State/province [120] 0 0
St. Petersburg
Country [121] 0 0
Spain
State/province [121] 0 0
Barcelona
Country [122] 0 0
Spain
State/province [122] 0 0
Hospitalet de Llobregat, Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Las Palmas De Gran Canaria
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Palma de Mallorca
Country [126] 0 0
Spain
State/province [126] 0 0
Pamplona
Country [127] 0 0
Spain
State/province [127] 0 0
Valencia
Country [128] 0 0
Sweden
State/province [128] 0 0
Linkoping
Country [129] 0 0
Sweden
State/province [129] 0 0
Umea
Country [130] 0 0
Switzerland
State/province [130] 0 0
Basel
Country [131] 0 0
Switzerland
State/province [131] 0 0
Lausanne
Country [132] 0 0
Switzerland
State/province [132] 0 0
Zurich
Country [133] 0 0
Taiwan
State/province [133] 0 0
Tainan
Country [134] 0 0
Taiwan
State/province [134] 0 0
Taipei
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taoyuan
Country [136] 0 0
Ukraine
State/province [136] 0 0
Dnipropetrovsk
Country [137] 0 0
Ukraine
State/province [137] 0 0
Donetsk
Country [138] 0 0
Ukraine
State/province [138] 0 0
Kharkiv
Country [139] 0 0
Ukraine
State/province [139] 0 0
Kyiv
Country [140] 0 0
Ukraine
State/province [140] 0 0
Lviv
Country [141] 0 0
Ukraine
State/province [141] 0 0
Sumy
Country [142] 0 0
Ukraine
State/province [142] 0 0
Uzhgorod
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Cambridge
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Glasgow
Country [145] 0 0
United Kingdom
State/province [145] 0 0
London
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Manchester
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Southampton
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
Trial website
https://clinicaltrials.gov/study/NCT01597908
Trial related presentations / publications
Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandala M, Haanen JBAG, Lebbe C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16.
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01597908